[Editorial: Importance of cardioselectivity and sympaticomimetric potential of beta-blockers (author's transl)].
D000070:Acebutolol / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000145:classification / Q000494:pharmacology*; D000526:Alprenolol / Q000494:pharmacology; D001808:Blood Vessels / Q000187:drug effects; D004983:Ethanolamines / Q000494:pharmacology; D006321:Heart / Q000187:drug effects*; D006801:Humans; D010096:Oxprenolol / Q000494:pharmacology; D010869:Pindolol / Q000494:pharmacology; D011217:Practolol / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D013015:Sotalol / Q000494:pharmacology; D013566:Sympathomimetics / Q000494:pharmacology
D000319:Adrenergic beta-Antagonists; D004983:Ethanolamines; D013566:Sympathomimetics; D010096:Oxprenolol; D000070:Acebutolol; D000526:Alprenolol; D011433:Propranolol; D013015:Sotalol; D010869:Pindolol; D011217:Practolol
Editorial: Was ist von Kardioselektivität und sympathikomimetischer Eigenwirkung von Beta-Rezeptorenblockern zu halten?